Stent Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Drug-Eluting Stent, Bare Metal Coronary Stent, Bioabsorbable Stent, Others), By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region & Competition, 2020-2030F

Market Overview

Global Stent Market was valued at USD 15.04 Billion in 2024 and is expected to reach USD 34.75 Billion by 2030 with a CAGR of 4.38%. Stents, which are small mesh tubes used to support weakened or narrowed arteries, play a vital role in treating conditions such as coronary artery disease, peripheral artery disease, and other vascular complications. A key factor contributing to market expansion is the growing incidence of lifestyle-related diseases, including hypertension, diabetes, and obesity, which significantly increase the risk of arterial blockages. As the global population ages and urban lifestyles become more sedentary, the demand for stenting procedures is expected to rise correspondingly.

This trend is especially prominent in both developed economies with aging populations and developing regions experiencing an epidemiological transition. Despite the positive outlook, the market faces several challenges. The high cost of advanced stent systems can limit access in low- and middle-income countries. In addition, stringent regulatory approval processes and concerns over the long-term performance of some newer technologies may slow the pace of adoption.

Key Market Drivers

Growth in Healthcare Industry

The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most substantial and lucrative segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. The ongoing growth of the global healthcare industry is playing a pivotal role in driving the expansion of the global stent market. As healthcare systems worldwide continue to strengthen, there has been a marked increase in the availability and accessibility of advanced medical treatments, particularly for cardiovascular diseases. The rise in healthcare spending both from public and private sectors has led to significant improvements in hospital infrastructure, interventional cardiology units, and diagnostic capabilities, all of which contribute to the growing demand for stents.

Cardiovascular diseases remain one of the leading causes of death globally, and their rising prevalence has heightened the need for effective, minimally invasive treatment options. Cardiovascular diseases (CVDs) represent the foremost cause of mortality worldwide, accounting for approximately 17.9 million deaths annually. Over 80% of these fatalities result from heart attacks and strokes, with nearly one-third occurring prematurely in individuals below the age of 70. The stent, a key device used in procedures such as angioplasty, has become a standard of care in managing conditions like coronary artery disease. As healthcare institutions adopt more technologically advanced equipment and procedures, the use of stents has increased in both developed and developing countries.

Surge in Technological Advancements

The global stent market is witnessing robust growth, primarily fueled by a surge in technological advancements that are reshaping the landscape of cardiovascular and peripheral vascular treatments. Continuous innovation in stent design, materials, drug delivery systems, and imaging technologies is enhancing the safety, efficacy, and long-term outcomes of stent-based interventions, thereby accelerating market demand across the healthcare sector. Recent advancements in bioresorbable stent technology are set to significantly reshape the field of interventional cardiology, especially in the treatment of below-the-knee peripheral artery disease (PAD). Notably, Abbott’s Esprit stent an evolution of the earlier Absorb bioresorbable platform has secured FDA approval and has shown promising outcomes in clinical trials.

One of the most significant technological shifts in the market has been the transition from bare-metal stents to drug-eluting stents (DES). These advanced stents are designed to release therapeutic agents that prevent restenosis, a common complication associated with earlier stent technologies. The latest generations of DES feature thinner struts and improved polymer coatings, which promote faster endothelial healing and reduce the incidence of late-stage thrombosis, contributing to their widespread clinical adoption.

Download Free Sample Report

Key Market Challenges

Limited Accessibility of Stents

Limited accessibility of stents remains a significant challenge in the global stent market, particularly in low- and middle-income countries. While stent technology has advanced considerably in recent years offering improved outcomes and less invasive treatment options the benefits are not equally distributed across all regions. Many patients in underserved areas continue to face barriers to timely and affordable access to these life-saving devices.

One of the main factors contributing to limited accessibility is the high cost associated with stent procedures. Advanced stents, such as drug-eluting and bioresorbable variants, are often priced beyond the reach of public healthcare systems in developing nations. The expenses are not limited to the devices themselves but extend to related costs such as diagnostic tests, surgical fees, hospitalization, and post-operative care. In the absence of robust insurance coverage or government subsidies, many patients are forced to forgo treatment or opt for lower-quality alternatives.

Key Market Trends

Growing Development of 3D-Printed Stents

The emergence of 3D-printed stents represents a transformative trend in the global stent market, driven by the demand for patient-specific solutions and advancements in additive manufacturing technology. Unlike conventional stents, which are manufactured in standard sizes using laser-cutting techniques, 3D printing enables the production of customized stents tailored precisely to the anatomical requirements of individual patients. This level of personalization enhances procedural accuracy, improves clinical outcomes, and reduces complications such as stent malapposition and restenosis. Notably, the patient-specific stents developed by Dr. Gildea and his engineering team at the Cleveland Clinic are engineered through the use of CT imaging and proprietary 3D visualization software. Customized molds are produced via 3D printing and subsequently filled with medical-grade silicone. This advanced manufacturing process ensures a precise anatomical fit tailored to each individual patient.

One of the key advantages of 3D-printed stents lies in their design flexibility. Medical engineers can optimize stent geometry to ensure better expansion, drug delivery capabilities, and structural integrity, particularly in complex or irregular vascular anatomies. This has opened new avenues in treating patients with atypical arterial conditions who previously faced limitations with traditional stent sizes and shapes. Moreover, the integration of bioresorbable and shape-memory polymers in 3D-printed stents is gaining traction. These materials allow the stents to provide temporary scaffolding during the healing process and then gradually dissolve within the body, eliminating the long-term risks associated with permanent implants.

Segmental Insights

Product Type Insights

Based on Product Type, Drug-Eluting Stent have emerged as the fastest growing segment in the Global Stent Market in 2024. This is due to their superior clinical performance, lower risk of restenosis, and increasing physician and patient preference for advanced cardiovascular treatment options. These stents, which gradually release antiproliferative drugs to prevent the re-narrowing of arteries, represent a significant advancement over traditional bare-metal stents. The evolution of DES technology has also contributed to the segment’s rapid expansion. Recent generations feature ultra-thin struts, biocompatible or bioresorbable polymers, and improved drug formulations, which collectively enhance safety and promote faster endothelial healing.

End Use Insights

Based on End Use, Hospitals & Clinics have emerged as the fastest growing segment in the Global Stent Market during the forecast period. Healthcare settings are often equipped with state-of-the-art catheterization labs, experienced interventional cardiologists, and comprehensive post-operative care facilities, making them the preferred choice for stent implantation procedures. As cardiovascular diseases continue to rise globally particularly in aging populations hospitals and clinics are witnessing a significant increase in admissions for conditions such as coronary artery disease, peripheral artery disease, and carotid artery stenosis.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Stent Market in 2024. This is primarily due to its advanced healthcare infrastructure, high adoption of innovative medical technologies, and a strong prevalence of cardiovascular diseases. The region, particularly the United States, boasts a well-established network of interventional cardiology centers and catheterization laboratories, enabling widespread use of stents in both elective and emergency procedures. This is further supported by the availability of highly trained healthcare professionals and robust reimbursement frameworks that encourage the early adoption of cutting-edge stent technologies.

Recent Development

• In May 2024, Abbott, a leading global healthcare company, announced the launch of its XIENCE Sierra Everolimus-Eluting Coronary Stent System in India. As the latest addition to the XIENCE stent portfolio, XIENCE Sierra is designed to treat patients with blocked coronary arteries. It incorporates the same advanced drug-eluting coating used in other XIENCE stents, which significantly reduces the risk of artery re-narrowing. The XIENCE stent family boasts an exceptional safety profile, supported by over 120 clinical studies and data from more than 120,000 patients. Notably, XIENCE Sierra offers an enhanced expansion range, making it particularly effective for treating vessels that vary in diameter at different points.
• In May 2025, Terumo Interventional Systems, a division of Terumo Corporation, announced the early commercial launch of its FDA-approved Roadsaver carotid stent system. According to the company, the Roadsaver features a dual-layer micromesh structure and a closed-cell design that delivers the flexibility typically associated with open-cell stents. This combination enhances adaptability and wall apposition in challenging anatomies. The system is engineered to secure plaque against the vessel wall, minimizing the risk of plaque protrusion and providing protection against distal embolization.
• In November 2024, Bentley announced the successful completion of the first-in-human implantation of its newly CE-certified BeFlared stent graft system, representing a significant milestone in the field of vascular intervention. The company highlighted that the BeFlared system is the world’s first stent specifically engineered as a dedicated bridging solution for fenestrated endovascular aneurysm repair (FEVAR), addressing a critical need in complex aortic procedures. This achievement not only underscores Bentley’s commitment to advancing endovascular technology but also sets a new benchmark for innovation and patient-specific treatment in the management of abdominal and thoracoabdominal aortic aneurysms. The successful procedure reinforces the clinical potential of the BeFlared system and paves the way for broader adoption across specialized vascular centers globally.
• In June 2024, Royal Philips, a global leader in health technology, announced the successful first implantation of the Duo Venous Stent System, an implantable medical device developed to address symptomatic venous outflow obstruction in patients suffering from chronic venous insufficiency (CVI). This milestone follows the receipt of premarket approval (PMA) from the U.S. Food and Drug Administration (FDA). Specifically designed to accommodate the complex anatomy and obstructions of the venous system, the Duo Venous Stent System includes two distinct stents Duo Hybrid and Duo Extend available in multiple sizes. The Duo Hybrid stent features an integrated design that incorporates multiple zones with varying mechanical properties within a single structure, optimizing performance for targeted venous support.

Key Market Players

• Medtronic plc
• B. Braun Melsungen AG
• Terumo Corporation
• STENTYS SA
• MicroPort Scientific Corporation
• Meril Life Sciences Pvt. Ltd
• Translumina GmbH
• Biosensors International Group Limited        
• Boston Scientific Corporation
• BIOTRONIK SE & Co. KG

Report Scope

In this report, the Global Stent Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Stent Market, By Product Type:

o   Drug-Eluting Stent

o   Bare Metal Coronary Stent

o   Bioabsorbable Stent

o   Others

• Stent Market, By End Use:

o   Hospitals & Clinics

o   Ambulatory Surgical Centers

o   Others

• Stent Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Stent Market.

Available Customizations:

Global Stent Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Stent Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]